Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia

INTRODUCTION: Once-weekly semaglutide is a novel glucagon-like peptide-1 (GLP-1) analogue for the treatment of type 2 diabetes that was associated with greater reductions in glycated hemoglobin (HbA1c) and body mass index (BMI) versus once-daily GLP-1 analogue liraglutide in a recent network meta-an...

Descripción completa

Detalles Bibliográficos
Autores principales: Malkin, Samuel J. P., Russel-Szymczyk, Monika, Liidemann, Girtel, Volke, Vallo, Hunt, Barnaby
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349296/
https://www.ncbi.nlm.nih.gov/pubmed/30535837
http://dx.doi.org/10.1007/s13300-018-0542-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349296/
https://www.ncbi.nlm.nih.gov/pubmed/30535837
http://dx.doi.org/10.1007/s13300-018-0542-x

Ejemplares similares